Abstract: The present disclosure provides anti-CCR4 chimeric antigen receptors (CARs) and compositions and methods for modified immune cells or precursors thereof (e.g., modified T cells) comprising anti-CCR4 CARs. Also provided are methods of using the anti-CCR4 CAR-expressing cells to treat cancer and T cell-depleting systems for use in combination with anti-CCR4 CAR T cell therapy.

Abstract: A vehicle according to the present disclosure includes a first riding space and a second riding space, each of which is a riding position on one side and the other side of a right side and a left side with respect to a front-rear direction, respectively, and is configured to: acquire a traveling route; identify a side where a landscape viewed from the vehicle is good from among the right side and the left side with respect to a traveling direction; identify a preferential space in which a degree of preferential treatment of a passenger riding in the first riding space or the second riding space is high; and determine the forward direction and the backward direction when the vehicle travels on the traveling route such that the preferential space is set to the side where the landscape viewed from the vehicle is good.

Abstract: An order reception system according to the present disclosure includes one or more processors. The one or more processors are configured to perform receiving a reservation from a user to provide a dish to a dish providing place, receiving the reservation to provide a dish, calculating a lead time required for providing the dish and an arrival time at which the user arrives at the dish providing place, and instructing the dish providing place to start preparing to provide the dish based on the arrival time and the lead time.

Abstract: The drive route generation device according to the present disclosure is configured to execute a process of acquiring a designated point, a process of acquiring a designation condition for a drive route to be generated, a process of selecting one or a plurality of specific spots from a plurality of spots based on the position information and the designation condition for the plurality of spots, and a process of generating, as a drive route, a circulation route that comes back to a designated point via one or a plurality of specific spots using the designated point as a departure point.

Abstract: To provide a pharmaceutical composition capable of enhancing the effect of an immune checkpoint inhibitor against tumor or cancer in a subject. Provided is a pharmaceutical composition that comprises bacterial cells, a culture supernatant, a metabolite, and/or a bacterial cell extract of Ruminococcaceae enterobacterium, and is administered in combination with an immune checkpoint inhibitor.

Abstract: It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.

Abstract: A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.

Abstract: The present disclosure provides a specific marker for identifying T cells specifically attacking cancer cells and the utilization of the marker. According to the present disclosure, a marker that has a high specificity for identifying T cells specifically attacking cancer cells is provided. According to the present disclosure, treatment or prevention of cancer in a subject with the use of a cell subpopulation contained in a tumor tissue infiltrating CD106+ T cell population or cells expressing a T cell receptor (TCR) expressed thereby can be provided. According to another embodiment of the present disclosure, a method for producing a cellular medicine can be provided. According to the present disclosure, further, a method that comprises using the amount of a cell subpopulation as an index of the responsiveness of a subject to a cancer immunotherapy can be provided. According to the present disclosure, furthermore, a method for acquiring a tumor specific TCR sequence can be provided.

Abstract: The object of the present invention is to provide a method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on those. The present invention can provide agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing the evaluation items consisting of combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8+ T cells in tumor tissue or blood.

Abstract: An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.

Abstract: In an effector type regulatory T cell detecting method using flow cytometry, a control sample containing a CD4-positive T cell population is measured, and based on a result of measuring the control sample, a FOXP3 level as a division reference for dividing a FOXP3-positive T cell population contained in the CD4-positive T cell population at a predetermined ratio is acquired as a reference value to be used for measuring a biological sample. A biological sample containing a CD4-positive T cell population is measured, and based on a result of measuring the biological sample, effector type regulatory T cells are detected from a cell population having a FOXP3 level higher than the reference value.

Abstract: The present invention provides a composition for preventing or treating a graft-versus-host disease, the composition comprising a fecal microbiota.

Abstract: The present invention provides a composition for preventing or treating a graft-versus-host disease, the composition comprising a fecal microbiota.

Abstract: It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.

Abstract: An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.

Abstract: The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells using bacteria having a type III secretion system.

Abstract: The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells using bacteria having a type III secretion system.

Abstract: The invention relates to stimulation of immune responses against antigen(s) and overcoming regulatory T cell suppression of such immune responses against antigen(s).